Low expression of MicroRNA-126 is associated with poor prognosis in colorectal cancer

Genes Chromosomes and Cancer

Volumn 53, Issue 4, 2014, Pages 358-365

  Liu, Yaling ^a   Zhou, Yu ^b   Feng, Xiao ^b   Yang, Pengchun ^b   Yang, Jingfang ^b   An, Ping ^a   Wang, Hao ^b   Ye, Shicai ^b   Yu, Caiyuan ^b   He, Yanting ^b   Luo, Hesheng ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, CXCR4; TUMOR MARKERS, BIOLOGICAL;

EID: 84894040795     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22146     Document Type: Article

References (39)

1. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. 2008. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27:2128-2136.
2. Babashah S, Soleimani M. 2011. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer 47:1127-1137.
3. Bachet JB, Marechal R, Demetter P, Bonnetain F, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Vaillant JC, Andre T, Closset J, Salmon I, Emile JF, Van Laethem JL. 2012. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol 23:2327-2335.
4. Balkwill F. 2004. Cancer and the chemokine network. Nat Rev Cancer 4:540-550.
5. Barbieri F, Bajetto A, Stumm R, Pattarozzi A, Porcile C, Zona G, Dorcaratto A, Ravetti JL, Minuto F, Spaziante R, Schettini G, Ferone D, Florio T. 2008. Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clin Cancer Res 14:5022-5032.
6. Bartel DP. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
7. Calin GA, Croce CM. 2006. MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866.
8. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. 2011. MicroRNA in prostate, bladder, and kidney cancer: A systematic review. Eur Urol 59:671-681.
9. Chen H, Miao R, Fan J, Han Z, Wu J, Qiu G, Tang H, Peng Z. 2013. Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma. Clin Exp Metastasis 30:651-658.
10. Cho WC. 2007. OncomiRs: The discovery and progress of microRNAs in cancers. Mol Cancer 6:60.
11. Diaz R, Silva J, Garcia JM, Lorenzo Y, Garcia V, Pena C, Rodriguez R, Munoz C, Garcia F, Bonilla F, Dominguez G. 2008. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 47:794-802.
12. Esquela-Kerscher A, Slack FJ. 2006. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6:259-269.
13. Feng R, Chen X, Yu Y, Su L, Yu B, Li J, Cai Q, Yan M, Liu B, Zhu Z. 2010. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 298:50-63.
14. Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K. 2008. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 47:939-946.
15. Ishihara K, Sasaki D, Tsuruda K, Inokuchi N, Nagai K, Hasegawa H, Yanagihara K, Kamihira S. 2012. Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol 36:560-565.
16. Jiang Z, Guo J, Xiao B, Miao Y, Huang R, Li D, Zhang Y. 2010. Increased expression of miR-421 in human gastric carcinoma and its clinical association. J Gastroenterol 45:17-23.
17. Jusufovic E, Rijavec M, Keser D, Korosec P, Sodja E, Iljazovic E, Radojevic Z, Kosnik M. 2012. let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non-small-cell lung cancer. PLoS One 7:e45577.
18. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, Hoon DS. 2005. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23:2744-2753.
19. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, Kawaguchi M, Kobayashi H, Doi R, Hori T, Fujii N, Imamura M. 2000. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: A possible role for tumor progression. Clin Cancer Res 6:3530-3535.
20. Li XM, Wang AM, Zhang J, Yi H. 2011. Down-regulation of miR-126 expression in colorectal cancer and its clinical significance. Med Oncol 28:1054-1057.
21. Li J, Du L, Yang Y, Wang C, Liu H, Wang L, Zhang X, Li W, Zheng G, Dong Z. 2013a. MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2. Cancer Lett 329:84-90.
22. Li Z, Li N, Wu M, Li X, Luo Z, Wang X. 2013b. Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. Mol Cell Biochem 381:233-242.
23. Liu B, Peng XC, Zheng XL, Wang J, Qin YW. 2009. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 66:169-175.
24. Liu Y, Zhou Y, Feng X, An P, Quan X, Wang H, Ye S, Yu C, He Y, Luo H. 2014. MicroRNA-126 functions as a tumor suppressor in colorectal cancer cells by targeting CXCR4 via the AKT and ERK1/2 signaling pathways. Int J Oncol 44:203-210.
25. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56.
26. Nair VS, Maeda LS, Ioannidis JP. 2012. Clinical outcome prediction by microRNAs in human cancer: A systematic review. J Natl Cancer Inst 104:528-540.
27. Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, Pozzi V, Carbonari D, Bracci M, Pignotti E, Mazzanti P, Sabbatini A, Ranaldi R, Gasparini S, Neuzil J, Tomasetti M. 2011. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One 6:e18232.
28. Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
29. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. 2004. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64:3753-3756.
30. Tan CT, Chu CY, Lu YC, Chang CC, Lin BR, Wu HH, Liu HL, Cha ST, Prakash E, Ko JY, Kuo ML. 2008. CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. Carcinogenesis 29:1519-1527.
31. Tang W, Zhu J, Su S, Wu W, Liu Q, Su F, Yu F. 2012. MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One 7:e51702.
32. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J. 2008. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451:147-152.
33. Teicher BA, Fricker SP. 2010. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16:2927-2931.
34. Tomasetti M, Staffolani S, Nocchi L, Neuzil J, Strafella E, Manzella N, Mariotti L, Bracci M, Valentino M, Amati M, Santarelli L. 2012. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem 45:575-581.
35. Walter BA, Valera VA, Pinto PA, Merino MJ. 2013. Comprehensive microRNA profiling of prostate cancer. J Cancer 4:350-357.
36. Wang B, Wang W, Niu W, Liu E, Liu X, Wang J, Peng C, Liu S, Xu L, Wang L, Niu J. 2013. SDF-1/CXCR4 axis promotes directional migration of colorectal cancer cells through upregulation of integrin alphavbeta6. Carcinogenesis.
37. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM. 2008. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 3:e2557.
38. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, Amadori D, Lu X, Xie D, Li QJ, Wang XF. 2013. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol 15:284-294.
39. Zhou Y, Feng X, Liu YL, Ye SC, Wang H, Tan WK, Tian T, Qiu YM, Luo HS. 2013. Downregulation of miR-126 is associated with colorectal cancer cells proliferation, migration and invasion by targeting IRS-1 via the AKT and ERK1/2 signaling pathways. PLoS One 8:e81203.